The proactive planning of risk minimisation measures (RMMs) in the context of optimizing the benefit-risk profiles of medicinal product is a challenging task. RMMs should be commensurate to the risk in relation to the clinical benefit of the product and should work for the intended patient population without adding undue burden on the healthcare systems. They should also allow for rapid evaluation of their effectiveness and adaptation to a changing healthcare environment, if and when necessary.